$RPTX
Repare Therapeutics Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022014820 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $112.5M $679.0K $408.0K
YoY Change 40383.81% 143.37% 140.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.904M $7.938M $8.779M
YoY Change 19.83% 17.76% 67.54%
% of Gross Profit
Research & Development $31.24M $31.48M $26.46M
YoY Change 23.19% 55.78% 60.26%
% of Gross Profit
Depreciation & Amortization $484.0K $523.0K $516.0K
YoY Change 31.17% 26.33% 60.25%
% of Gross Profit
Operating Expenses $39.15M $39.41M $35.24M
YoY Change 22.5% 46.27% 62.04%
Operating Profit $73.40M -$38.73M -$34.83M
YoY Change -331.7% 45.25% 61.39%
Interest Expense $2.153M $685.0K $112.0K
YoY Change 2403.49% -1323.21% 273.33%
% of Operating Profit 2.93%
Other Income/Expense, Net $2.116M $674.0K $104.0K
YoY Change 2578.48% -1169.84% 300.0%
Pretax Income $75.52M -$38.06M -$34.73M
YoY Change -338.97% 42.39% 61.11%
Income Tax $54.00K $33.00K $32.00K
% Of Pretax Income 0.07%
Net Earnings $75.46M -$38.09M -$34.76M
YoY Change -344.27% 44.79% 62.29%
Net Earnings / Revenue 67.05% -5610.16% -8518.87%
Basic Earnings Per Share $1.80 -$0.91 -$0.83
Diluted Earnings Per Share $1.71 -$0.91 -$830.3K
COMMON SHARES
Basic Shares Outstanding 41.94M 41.90M 41.87M
Diluted Shares Outstanding 44.18M 41.90M 41.86M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $155.2M $275.8M $305.1M
YoY Change -40.54% -6.06% -2.01%
Cash & Equivalents $155.2M $275.8M $305.1M
Short-Term Investments $215.2M $6.255M $6.528M
Other Short-Term Assets $5.635M $3.242M $3.915M
YoY Change -38.1% 52.28% 0.38%
Inventory
Prepaid Expenses $5.635M $3.242M $3.915M
Receivables
Other Receivables
Total Short-Term Assets $390.6M $289.7M $319.2M
YoY Change 39.31% -6.29% -2.73%
LONG-TERM ASSETS
Property, Plant & Equipment $4.683M $5.124M $5.397M
YoY Change 12.44% 20.99% -38.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $497.0K $497.0K $586.0K
YoY Change -50.69% 45.75% -72.1%
Total Long-Term Assets $18.56M $18.31M $17.92M
YoY Change 21.56% 59.7% 64.41%
TOTAL ASSETS
Total Short-Term Assets $390.6M $289.7M $319.2M
Total Long-Term Assets $18.56M $18.31M $17.92M
Total Assets $409.2M $308.0M $337.1M
YoY Change 38.4% -3.93% -0.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.345M $4.991M $1.546M
YoY Change 402.42% 51.11% -54.53%
Accrued Expenses $17.49M $22.00M $18.47M
YoY Change 44.72% 116.52% 184.08%
Deferred Revenue $34.78M $11.86M $11.87M
YoY Change 289.74% 35.28%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $61.87M $39.44M $34.08M
YoY Change 164.29% 69.83% 174.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $41.51M $43.09M $44.41M
YoY Change -23.1% -17.68% -24.74%
Total Long-Term Liabilities $41.51M $43.09M $44.41M
YoY Change -23.1% -17.68% -24.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $61.87M $39.44M $34.08M
Total Long-Term Liabilities $41.51M $43.09M $44.41M
Total Liabilities $103.4M $82.53M $78.49M
YoY Change 33.58% 9.22% 9.93%
SHAREHOLDERS EQUITY
Retained Earnings -$207.7M -$283.1M -$245.0M
YoY Change 14.11% 87.39%
Common Stock $514.0M $508.6M $503.7M
YoY Change 28.42% 28.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $305.8M $225.5M $258.7M
YoY Change
Total Liabilities & Shareholders Equity $409.2M $308.0M $337.1M
YoY Change 38.4% -3.93% -0.58%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income $75.46M -$38.09M -$34.76M
YoY Change -344.27% 44.79% 62.29%
Depreciation, Depletion And Amortization $484.0K $523.0K $516.0K
YoY Change 31.17% 26.33% 60.25%
Cash From Operating Activities $88.16M -$28.19M -$30.01M
YoY Change -369.0% 56.15% 110.91%
INVESTING ACTIVITIES
Capital Expenditures -$266.0K -$1.569M $487.0K
YoY Change -17.9% 264.04% -36.92%
Acquisitions
YoY Change
Other Investing Activities -$208.7M $260.0K $890.0K
YoY Change 320921.54% -16.67%
Cash From Investing Activities -$208.9M -$1.309M $403.0K
YoY Change 53609.51% 1000.0% -152.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 269.0K 205.0K 241.0K
YoY Change -25.9% -54.65% 31.69%
NET CHANGE
Cash From Operating Activities 88.16M -28.19M -30.01M
Cash From Investing Activities -208.9M -1.309M 403.0K
Cash From Financing Activities 269.0K 205.0K 241.0K
Net Change In Cash -120.5M -29.30M -29.29M
YoY Change 267.4% 65.31% 98.15%
FREE CASH FLOW
Cash From Operating Activities $88.16M -$28.19M -$30.01M
Capital Expenditures -$266.0K -$1.569M $487.0K
Free Cash Flow $88.42M -$26.62M -$30.49M
YoY Change -372.5% 51.07% 103.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
632000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
19.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0072
us-gaap Variable Lease Cost
VariableLeaseCost
110000
dei Entity Registrant Name
EntityRegistrantName
Repare Therapeutics Inc.
dei Entity Address Address Line1
EntityAddressAddressLine1
7210 Frederick-Banting
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
St-Laurent
dei Entity Address State Or Province
EntityAddressStateOrProvince
QC
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
H4S 2A1
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
412-7018
dei Security12b Title
Security12bTitle
Common shares, no par value
dei Trading Symbol
TradingSymbol
RPTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-558000
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41937795
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
308044000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57933000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36714000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
368715000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7938000
CY2022Q2 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
679000
CY2021Q2 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
279000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6741000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16717000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11978000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
39413000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
26946000
us-gaap Operating Expenses
OperatingExpenses
74650000
us-gaap Operating Expenses
OperatingExpenses
48692000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-38734000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-26667000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
275834000
us-gaap Operating Income Loss
OperatingIncomeLoss
-73563000
us-gaap Operating Income Loss
OperatingIncomeLoss
-48247000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
141000
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-94000
rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
1087000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
124000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
334427000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-125000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
6255000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
7439000
CY2022Q2 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
2598000
CY2021Q4 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
2580000
CY2022Q2 us-gaap Income Tax Receivable
IncomeTaxReceivable
799000
CY2021Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
0
CY2022Q2 us-gaap Other Receivables
OtherReceivables
1010000
CY2022Q2 us-gaap Investment Income Net
InvestmentIncomeNet
544000
CY2021Q4 us-gaap Other Receivables
OtherReceivables
654000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3242000
CY2021Q2 us-gaap Investment Income Net
InvestmentIncomeNet
38000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6314000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
289738000
us-gaap Investment Income Net
InvestmentIncomeNet
673000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
351414000
us-gaap Investment Income Net
InvestmentIncomeNet
102000
CY2022Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
11000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5124000
rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
445000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
225517000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
288421000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5604000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6456000
CY2021 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
dei Entity Central Index Key
EntityCentralIndexKey
0001808158
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A8
CY2021 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39335
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7491000
CY2021Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
7000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
19000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
497000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
586000
CY2022Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
6229000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
14000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3620000
CY2022Q2 us-gaap Assets
Assets
308044000
CY2021Q4 us-gaap Assets
Assets
368715000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4991000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2302000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
20459000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18622000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
674000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-63000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2135000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
778000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1721000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11855000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11921000
CY2022Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
523000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
39440000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35089000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4495000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5592000
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
38592000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-37000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38060000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
39613000
CY2022Q2 us-gaap Liabilities
Liabilities
82527000
CY2021Q4 us-gaap Liabilities
Liabilities
80294000
CY2022Q2 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2021Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31475000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20205000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2021Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41923472
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41923472
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41850162
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41850162
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
481380000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
480699000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
27253000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17988000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-283116000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-210266000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26730000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72785000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48284000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
33000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-421000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65000
CY2022Q2 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-38093000
CY2021Q2 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-26309000
rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-72850000
rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-47726000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38093000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-38093000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26309000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-26309000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-72850000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-72850000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47726000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-47726000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.29
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41899509
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41899509
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37036683
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37036683
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41880666
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41880666
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36977040
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36977040
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
286830000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
183000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2057000
CY2021Q1 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-21417000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
267653000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
449000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3183000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
113000
CY2021Q2 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-26309000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
245089000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
288421000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4755000
CY2022Q1 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-34757000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
258660000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
205000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4745000
CY2022Q2 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-38093000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
225517000
us-gaap Profit Loss
ProfitLoss
-72850000
us-gaap Profit Loss
ProfitLoss
-47726000
us-gaap Share Based Compensation
ShareBasedCompensation
9500000
us-gaap Share Based Compensation
ShareBasedCompensation
5240000
us-gaap Depreciation
Depreciation
1039000
us-gaap Depreciation
Depreciation
734000
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
1091000
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
748000
rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
136000
rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
13000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-34000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-54000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
2609000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
626000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3072000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-4622000
rptx Increase Decrease In Research And Development Tax Credits Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable
31000
rptx Increase Decrease In Research And Development Tax Credits Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable
627000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
358000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-556000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-89000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2698000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1155000
rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
3334000
rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
4509000
rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
460000
rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
-272000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-1322000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
44000
rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-1123000
rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-238000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1087000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-445000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58199000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32285000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2056000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1201000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
5150000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3750000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
4000000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
3438000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-906000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-889000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
233000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
632000
rptx Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
213000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
446000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-58593000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-32543000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
334427000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
326396000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
275834000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
293853000
CY2022Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
275834000
CY2021Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
293635000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
218000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
275834000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
293853000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
222000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
38000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
56000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
705000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2016-09-06
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">assumptions </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">reflected in these unaudited condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation, right-of-use assets and lease liabilities and income taxes. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p>
CY2022Q2 rptx Fair Value Assets Transfers Between All Levels
FairValueAssetsTransfersBetweenAllLevels
0
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
224995000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
224995000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9974000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
9974000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3694000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4867000
CY2022Q2 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
15106000
CY2021Q4 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
11272000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
844000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
387000
CY2022Q2 rptx Accrued Property And Equipment Purchases
AccruedPropertyAndEquipmentPurchases
222000
CY2021Q4 rptx Accrued Property And Equipment Purchases
AccruedPropertyAndEquipmentPurchases
1719000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
593000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
377000
CY2022Q2 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
20459000
CY2021Q4 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
18622000
rptx Number Of Operating Leases
NumberOfOperatingLeases
4
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
false
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
615000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
424000
us-gaap Operating Lease Cost
OperatingLeaseCost
1231000
us-gaap Operating Lease Cost
OperatingLeaseCost
843000
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
8000
CY2021Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
2000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
16000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
5000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
33000
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
54000
us-gaap Variable Lease Cost
VariableLeaseCost
100000
CY2022Q2 us-gaap Lease Cost
LeaseCost
656000
CY2021Q2 us-gaap Lease Cost
LeaseCost
480000
us-gaap Lease Cost
LeaseCost
1347000
us-gaap Lease Cost
LeaseCost
958000
us-gaap Operating Lease Payments
OperatingLeasePayments
802000
us-gaap Operating Lease Payments
OperatingLeasePayments
605000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
56000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
705000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M28D
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y10M24D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.040
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.046
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5322591
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.76
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2883567
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.54
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
56503
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.12
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
175252
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7974403
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.66
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
56503
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.12
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
200000
rptx Additional Paid In Capital Share Based Payment Arrangement Exercised Options Credited To Common Shares
AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares
100000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0292
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0092
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0200
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M2D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M2D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M19D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M26D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7885
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7644
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7855
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7559
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4745000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3183000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9500000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5240000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4745000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3183000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9500000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5240000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
49000000.0
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38093000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26309000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-72850000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47726000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38093000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-38093000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26309000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-26309000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-72850000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-72850000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47726000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-47726000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41899509
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41899509
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37036683
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37036683
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41880666
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41880666
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36977040
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36977040
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.29

Files In Submission

Name View Source Status
0000950170-22-014820-index-headers.html Edgar Link pending
0000950170-22-014820-index.html Edgar Link pending
0000950170-22-014820.txt Edgar Link pending
0000950170-22-014820-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img46999202_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rptx-20220630.htm Edgar Link pending
rptx-20220630.xsd Edgar Link pending
rptx-20220630_cal.xml Edgar Link unprocessable
rptx-20220630_def.xml Edgar Link unprocessable
rptx-20220630_htm.xml Edgar Link completed
rptx-20220630_lab.xml Edgar Link unprocessable
rptx-20220630_pre.xml Edgar Link unprocessable
rptx-ex10_1.htm Edgar Link pending
rptx-ex10_2.htm Edgar Link pending
rptx-ex31_1.htm Edgar Link pending
rptx-ex31_2.htm Edgar Link pending
rptx-ex32_1.htm Edgar Link pending
rptx-ex32_2.htm Edgar Link pending
rptx-ex5_1.htm Edgar Link pending
Show.js Edgar Link pending